Olmesartan Medoxomil Accord (Olmesartan Medoxomil)

Olmesartan Medoxomil is used to manage conditions related to the renin‑angiotensin system, primarily hypertension.

• Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk.
• Heart failure: may be added to standard therapy to improve afterload reduction.
• Diabetic nephropathy: helps slow progression of renal impairment in patients with type 2 diabetes.

• Olmesartan Medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation. This inhibition leads to vasodilation, reduced sodium and water retention, and ultimately lower arterial pressure without affecting bradykinin pathways.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: feeling unusually tired.
• Nausea: upset stomach or urge to vomit.
• Diarrhea: loose stools.
• Cough: dry, non‑productive cough.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat requiring emergency care.
• Hyperkalemia: elevated blood potassium that can affect heart rhythm.
• Acute renal failure: sudden loss of kidney function.
• Severe hypotension: dangerously low blood pressure, especially after dose escalation.
• Hepatic injury: abnormal liver enzymes or jaundice.
• Myocardial infarction: rare reports of heart attack in susceptible patients.

Before initiating therapy, consider the following precautions:

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with chronic kidney disease.
• Serum potassium: monitor for hyperkalemia, particularly when combined with potassium‑sparing agents.
• Hepatic impairment: use with caution in severe liver disease.
• Pregnancy: avoid use during pregnancy as safety has not been established.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Olmesartan Medoxomil can interact with several drug classes.

Major Interactions (Avoid)

• ACE inhibitors: concurrent use may increase risk of angioedema and hyperkalemia.
• Aliskiren (in diabetes): combined therapy can cause renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics: may lead to dangerous elevations in serum potassium.
• NSAIDs: can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely):\n- Thiazide diuretics: additive blood‑pressure lowering effect; monitor for hypotension.

• Lithium: may increase lithium concentrations; check lithium levels.
• CYP450 inhibitors/inducers: may modestly affect olmesartan plasma levels; adjust monitoring as needed.